Dose-response meta-analysis of antipsychotic drugs for acute schizophrenia

Cited by (301)

Items 101–200 of 301

1. Impact of minimal self disorders on naturalistic episodic memory in first-episode psychosis and parallels in healthy individuals with schizotypal traits
   Delphine Yeh, Sylvain Penaud, Alexandre Gaston‐Bellegarde, Linda Scoriels, Marie‐Odile Krebs, Pascale Piolino · 2024 · Frontiers in Psychiatry
2. Influence of C YP2D6 Genotypes and Phenotypes on the Plasma Levels and Clinical Response to Aripiprazole
   Cécile Gras, Marianna Piras, Setareh Ranjbar, Claire Grosu, François R. Girardin, Frederik Vandenberghe, Nicolas Ansermot, Carole Grandjean, Stefan Kaiser, Franziska Gamma et al. · 2025 · Schizophrenia Bulletin
3. Non-Clozapine interventions in treatment-resistant schizophrenia: a systematic review and meta-analysis
   Richard Carr, Alistair Cannon, Valeria Finelli, Bernard Roch Bukala, Yesim Cimen, Patritsiya Filipova, Connor Cummings, Toby Pillinger, Oliver David Howes, Robert Ali McCutcheon · 2025 · Molecular Psychiatry
4. Corollary Discharge Dysfunction to Inner Speech and its Relationship to Auditory Verbal Hallucinations in Patients with Schizophrenia Spectrum Disorders
   Thomas J. Whitford, Lawrence Kin-hei Chung, Oren Griffiths, Bradley N. Jack, Mike E. Le Pelley, K Spencer, Ana Rita Barreiros, Anthony W Harrison, Nathan Thomas Han, Sol Libesman et al. · 2025 · Schizophrenia Bulletin
5. Comparative Efficacy of Dopamine Partial Agonists by Doses for Treatment-Resistant Depression
   Itsuki Terao, Wakako Kodama · 2024 · Journal of Clinical Psychopharmacology
6. Randomized Laboratory Study of Single-Dose Cannabis, Dronabinol, and Placebo in Patients With Schizophrenia and Cannabis Use Disorder
   Mary F. Brunette, Robert M. Roth, Christi L. Trask, Jibran Younis Khokhar, James Ford, Soo Hwan Park, Sara M. Hickey, Thomas A. Zeffiro, Haiyi Xie · 2024 · Schizophrenia Bulletin
7. Associations between momentary mental states and concurrent social functioning after remission from first episode psychosis: A HAMLETT ecological momentary assessment study
   Matej Djordjevic, Hannah E. Jongsma, Claudia J.P. Simons, Priscilla P. Oomen, Lieuwe de Haan, Nynke Boonstra, Martijn Kikkert, Sanne Koops, Chris Neeltje Wil Geraets, Marieke Begemann et al. · 2024 · Journal of Psychiatric Research
8. A Critical Reappraisal of Haloperidol for Delirium Management in the Intensive Care Unit: Perspective from Psychiatry
   Shixie Jiang, Matthew G. Gunther · 2025 · Journal of Clinical Medicine
9. Electrochemical and Computational Studies of Aripiprazole as a Novel Eco-friendly Green Corrosion Inhibitor for Carbon Steel in Aqueous Environment
   Mai M. A. H. Shanab · 2021 · International Journal of Electrochemical Science
10. Validation of a quick and simple chromatographic method for simultaneous quantification of sertraline, escitalopram, risperidone and paliperidone levels in the human plasma
    Aleksandra Jeremić, F. Milosavljević, Sandra S. Vladimirov, Bojan Batinić, Bojan D. Marković, Marin M. Jukić · 2021 · Arhiv za farmaciju
11. Feasibility and Effect of Increasing Clozapine Plasma Levels in Long-Stay Patients With Treatment-Resistant Schizophrenia
    Jan P.A.M. Bogers, Peter F.J. Schulte, Theo G. Broekman, Lieuwe de Haan · 2023 · Journal of Clinical Psychopharmacology
12. Antipsychotic dose reduction: unclear benefits but certain risks
    Stefan Leucht, Irene Bighelli, Spyridon Siafis, Johannes Schneider‐Thoma, John M. Davis · 2023 · The Lancet Psychiatry
13. Single-arm meta-analysis of drug response in placebo-controlled versus active-controlled antipsychotic drug trials in schizophrenia
    Shimeng Dong, Johannes Schneider‐Thoma, Spyridon Siafis, Natalie Luise Peter, Stefan Leucht · 2024 · European Neuropsychopharmacology
14. Addressing Patients’ Unmet Needs to Improve Outcomes in Schizophrenia
    Philip D. Harvey, John Michael Kane · 2021 · The Journal of Clinical Psychiatry
15. Low-Dose Ziprasidone in Combination with Sertraline for First-Episode Drug-Naïve Patients with Schizophrenia: a Randomized Controlled Trial
    Cheng Zhu, Xiaoni Guan, Yuechan Wang, Jiahong Liu, Thomas R. Kosten, Meihong Xiu, Fengchun Wu, Xiangyang Zhang · 2022 · Neurotherapeutics
16. The Oral Bioavailability of Lurasidone is Impacted by Changes to the Gut Microbiome: Implications for Antipsychotic Therapy
    Kate Collins, Srinivas Kamath, Tahlia R. Meola, Anthony D. Wignall, Paul Joyce · 2024 · bioRxiv (Cold Spring Harbor Laboratory)
17. Antipsychotic dose and efficacy for acute schizophrenia spectrum disorders: an updated systematic review and dose-response meta-analysis
    Yuki Furukawa, Xiao Lin, Alessandro Rodolico, Jing Tian, Hui Wu, Johannes Schneider‐Thoma, Josef Priller, John M Davis, Stefan Leucht, Spyridon Siafis · 2026 · EClinicalMedicine
18. Haloperidol (oral) versus olanzapine (oral) for people with schizophrenia and schizophrenia-spectrum disorders
    Khasan Ibragimov, Gregory Keane, Cristina Carreño Glaría, Jie Jun Cheng, Augusto Eduardo Llosa · 2024 · Cochrane Database of Systematic Reviews
19. The risk of diabetes and HbA1c deterioration during antipsychotic drug treatment: A Danish two‐cohort study among patients with first‐episode schizophrenia
    Nanna M. Madsen, Marc A. Sørensen, Andreas Aalkjær Danielsen, Mikkel Højlund, Christopher Rohde, Ole Köhler‐Forsberg · 2024 · Acta Psychiatrica Scandinavica
20. Thinning of central foveal thickness in the retina of patients with schizophrenia
    Jiayi Zhu, Zijing Wang, Tianzhen Chen, Yun Zhou, Feikang Xu, Jiang Du, Min Zhao · 2024 · European Archives of Psychiatry and Clinical Neuroscience
21. Assessment of factors associated with antipsychotic-induced weight gain: A nationwide cohort study
    Shuhei Ishikawa, Naoki Hashimoto, Ryo Okubo, Ryo Sawagashira, Ryodai Yamamura, Yoichi Minagawa Ito, Norihiro Sato, Ichiro Kusumi · 2024 · Progress in Neuro-Psychopharmacology and Biological Psychiatry
22. Optimal Dose of Baclofen for the Treatment of Alcohol Use Disorder: A Systematic Review and Dose-Response Meta-analysis
    Kazumasa Kotake, Ryuhei So, Nozomu Hashimoto, Eriya Imai, Takao Kaneko, Masahiro Banno, Yuki Furukawa · 2025 · CNS Drugs
23. Measurement Based Care in a first episode psychosis program: Development of an algorithm of care based on the Clinical Global Impressions Scale
    Michelle Khau, Karim Tabbane, David Bloom, Sherezad Abadi, Celine Villemus, Mark Rabinovitch, Jai L. Shah, Alexandre Veillette, Srividya N. Iyer, Patricia Boksa et al. · 2022 · Journal of Psychiatric Research
24. Dose-response analysis of aripiprazole in patients with schizophrenia in Taiwan
    Yun Tien, Hsiang-Ping Huang, Ding‐Lieh Liao, Shang-Chien Huang · 2022 · Therapeutic Advances in Psychopharmacology
25. Towards full recovery with lurasidone: effective doses in the treatment of agitation, affective, positive and cognitive symptoms in schizophrenia, and dual psychosis
    María Teresa Guarro Carreras, Luis Jiménez Suárez, Laura Lago García, L. Montes Reula, Adrián Neyra, Francisco Acoidan Rodríguez Batista, Miguel Velasco Santos, Juan Luis Prados-Ojeda, Marina Díaz‐Marsá, Manuel Martı́n-Carrasco et al. · 2024 · Drugs in Context
26. A drug repurposing screen reveals dopamine signaling as a critical pathway underlying potential therapeutics for the rare disease DPAGT1-CDG
    Hans M. Dalton, Naomi J. Young, Alexys R. Berman, Heather D Evans, Sydney J Peterson, Kaylee A Patterson, Clement Y. Chow · 2024 · PLoS Genetics
27. Subcortical and insula functional connectivity aberrations and clinical implications in first-episode schizophrenia
    Bixin Wang, Meng Zhang, Fengmei Fan, Chunyu Yuan, Zhiren Wang, Yunlong Tan, Shuping Tan · 2024 · Asian Journal of Psychiatry
28. Lurasidone – pharmacodynamic and pharmacokinetic properties, clinical potential and interaction risk
    Marcin Siwek, Anna Julia Krupa, A Wasik · 2020 · Pharmacotherapy in Psychiatry and Neurology
29. Dosing antipsychotics in special populations of patients with schizophrenia: severe psychotic agitation, first psychotic episode and elderly patients
    Fayçal Mouaffak, Florian Ferreri, Julie Bourgin, Emmanuelle Baloche, Olivier J. Blin, Pierre Vandel, Ricardo Pablo Garay, Pierre Vidailhet, Emmanuelle Corruble, Pierre‐Michel Llorca · 2021 · Expert Opinion on Pharmacotherapy
30. A Candidate Gliotransmitter, L-β-Aminoisobutyrate, Contributes to Weight Gain and Metabolic Complication Induced by Atypical Antipsychotics
    Kouji Fukuyama, Eishi Motomura, Motohiro Okada · 2023 · Nutrients
31. Comparative efficacy of quetiapine by dose and formulation for psychosis in schizophrenia: A systematic review and dose–response model-based network meta-analysis
    Itsuki Terao, Asato Yokoi, Hirotaka Fukushima · 2023 · Journal of Psychopharmacology
32. The retina across the psychiatric spectrum: a systematic review and meta-analysis
    Nils Kallen, Giacomo Cecere, Dario Palpella, Finn Rabe, Foivos Georgiadis, Paul Badstübner, Victoria Edkins, Miriam Trindade, Stephanie Homan, Wolfgang Omlor et al. · 2024 · medRxiv
33. Comparison of Corticosteroid Regimens for COVID-19 and Non-COVID-19 ARDS
    Ryosuke Imai, Takayuki Niitsu, Monica Yun Liu, Hilary E. Faust, Lynn M. Schnapp, Shota Yamamoto · 2025 · CHEST Critical Care
34. Individuals with psychosis receive less electric field strength during transcranial direct current stimulation compared to healthy controls
    Rebecca Kazinka, Da Som Choi, Alexander Opitz, Kelvin O. Lim · 2024 · Schizophrenia
35. Population pharmacokinetics of brexpiprazole in Japanese healthy subjects and patients with schizophrenia
    Koushi Higashi, Tomohiro Sasaki, Kazuo Aoki, Daisuke Sekine, Kenji Maeda, Yuki Shiomi, Yosuke Kawai · 2025 · Drug Metabolism and Pharmacokinetics
36. Predictors of long-term outcome of patients with schizophrenia in Africa: systematic review and meta-analysis
    Mulualem Admasu Kelebie, Setegn Fentahun, Gebresilassie Tadesse, Girum Nakie, Girmaw Medfu Takelle, Birtukan Fasil, Gidey Rtbey, Mulu Muche, Melese Gobezie, Abenet Alazar et al. · 2025 · BMC Public Health
37. GABAA receptor availability in clinical high-risk and first-episode psychosis: a [11C]Ro15-4513 positron emission tomography study
    Paulina B. Lukow, Julia J. Schubert, Mario Severino, Samuel Knight, Amanda Kiemes, Nicholas R Livingston, James Davies, Andrea De Micheli, Thomas J. Spencer, Paolo Fusar‐Poli et al. · 2025 · Molecular Psychiatry
38. Beyond One-Size-Fits-All: Personalized Medicine and Future Directions in Sex-Based Psychopharmacological Treatment
    Marianna Mazza, Francesco Maria Lisci, Caterina Brisi, Gianandrea Traversi, Eleonora Gaetani, Roberto Pola, Giuseppe Marano · 2024 · Future Pharmacology
39. Exploring real-world prescribing patterns for maintenance treatment in bipolar disorders: a focus on antidepressants and benzodiazepines
    Sanja Andrić Petrović, Dusan Jankovic, Nina Kaurin, Vanja Mandić-Maravić, Danilo Pešić, Ivan Ristić, Nadja P. Marić · 2024 · International Journal of Psychiatry in Clinical Practice
40. Antipsychotic Medications: Enhancing Use to Improve Outcomes
    Hiroyoshi Takeuchi, Stefan Leucht, John Michael Kane, Ofer Agid, Gary J. Remington · 2021 · Schizophrenia Bulletin
41. The Perspectives of Early Diagnosis of Schizophrenia Through the Detection of Epigenomics-Based Biomarkers in iPSC-Derived Neurons
    Davin Lee, Jinsoo Seo, Hae chan Jeong, Hyosang Lee, Sung Bae Lee · 2021 · Frontiers in Molecular Neuroscience
42. Early improvement as a predictor of later response to lurasidone in schizophrenia from Japan trials: A diagnostic test
    Taro Kishi, Hiroshi Nakamura, Nakao Iwata · 2022 · Psychiatry and Clinical Neurosciences
43. Patterns of Impaired Neurocognitive Performance on the Global Neuropsychological Assessment, and Their Brain Structural Correlates in Recent-onset and Chronic Schizophrenia
    Vineeth Mohan, Pravesh Parekh, Ammu Lukose, Sydney Moirangthem, Jitender S. Saini, David J. Schretlen, John P. John · 2023 · Clinical Psychopharmacology and Neuroscience
44. Cerebrospinal fluid proteomics reveals synaptic and immune dysregulation in treatment-resistant schizophrenia
    Laura Elisabeth Fischer, Michael G. Gottschalk, Lars U. G. Reitz, Joanna Moussiopoulou, Nikolaos Koutsouleris, Vladislav Yakimov, Emanuel Boudriot, Sophie Seeburger, Tengjia Jiang, Johanna Weiske et al. · 2025 · medRxiv
45. Psychiatrists effect on positive symptom severity and daily functioning during pharmacotherapy for first-episode psychosis patients
    Franciska de Beer, Sanne Koops, Robert A. Schoevers, Wim Veling, Nico J.M. van Beveren, Lieuwe de Haan, Nynke Boonstra, Martijn Kikkert, Marieke Begemann, Iris E. Sommer et al. · 2024 · Scientific Reports
46. Cortisol response patterns to stress correlated to white matter integrity and duration of illness in patients with schizophrenia
    Xinyu Jiang, Mengzhuang Gou, Yi Yin, Wenjin Chen, Yanli Li, Song Chen, Shujuan Pan, Xingguang Luο, Shuping Tan, Baopeng Tian et al. · 2025 · Psychoneuroendocrinology
47. Sex differences in the efficacy and tolerability of antipsychotic drugs in people with an acute exacerbation of schizophrenia: protocol for an individual-participant-data, dose-response, network meta-analysis
    Spyridon Siafis, Yuki Furukawa, Johannes Schneider‐Thoma, Nobuyuki Nomura, Natalia E. Fares‐Otero, Bram W C Storosum, Jasper Brian Zantvoord, Christian J. Schwarz, Julia Schulz, Horst Naiser et al. · 2025 · F1000Research
48. Advances in implementation strategies for treatment adherence in schizophrenia: a narrative review
    Yan Shen, Xiaoli Wu · 2026 · Frontiers in Psychiatry
49. Updated rationale for the initial antipsychotic selection for patients with schizophrenia
    Matej Markota, Robert J. Morgan, Jonathan G. Leung · 2024 · Schizophrenia
50. Estimation of premorbid intelligence in schizophrenia: a systematic literature review
    Azeezat Aminu, Jane Elizabeth Aspell, Debora Vasconcelos e Sa, Peter Bright · 2025 · Journal of Clinical and Experimental Neuropsychology
51. Maintenance Therapy of Psychosis Spectrum Disorders in a Real-World Setting: Antipsychotics Prescription Patterns and Long-Term Benzodiazepine Use
    Nadja P. Marić, Sanja Andrić Petrović, Manuela Russo, Stefan Jerotić, Ivan Ristić, Bojana Savić, Tamara Pemovska, Miloš Milutinović, Emina Ribić, Silvana Markovska-Simoska et al. · 2022 · Frontiers in Psychiatry
52. Aripiprazole vs Risperidone Head-to-Head Effectiveness in First-Episode Non-Affective-Psychosis: A 3-Month Randomized, Flexible-Dose, Open-Label Clinical Trial
    Lucia Garrido-Sanchez, Marcos Gómez‐Revuelta, Víctor Ortiz‐García de la Foz, José María Pelayo‐Terán, María Juncal‐Ruíz, Miguel Ruíz-Veguilla, Jacqueline Mayoral-van Son, Rosa Ayesa‐Arriola, Javier Vázquez-Bourgón, Benedicto Crespo‐Facorro · 2022 · The International Journal of Neuropsychopharmacology
53. Case report: Amisulpride therapy induced reversible elevation of creatine kinase-MB and bradycardia in schizophrenia
    Zerui Hu, Zhenzhen Yang, Xu-Bo Wang, Hong-Shuo Chu, Chuanxin Liu · 2022 · Frontiers in Psychiatry
54. Therapeutic Appropriateness of Cariprazine in the Management of Schizophrenia: Experts’ Opinion using a Delphi Approach
    Bernardo Maria Dell’Osso, Antonello Bellomo, Andreas Conca, Virginio Salvi, Alberto Siracusano, Carmelo Zaffora, Domenico De Berardis, Massimo Di Giannantonio · 2023 · Current Neuropharmacology
55. A proposal for reducing maximum target doses of drugs for psychosis: Reviewing dose–response literature
    James Richard O’Neill, Adam Jameson, Samantha Louise McLean, Michael Dixon, Alastair G. Cardno, Christopher Lawrence · 2024 · Journal of Psychopharmacology
56. Olanzapine attenuates amyloid-β-induced microglia-mediated progressive neurite lesions
    Anjila Dongol, Yuanyi Xie, Peng Zheng, Xi Chen, Xu‐Feng Huang · 2024 · International Immunopharmacology
57. Trends in Antipsychotic Polypharmacy and Potential Overtreatment with Antipsychotics: A Naturalistic Cohort Study of People in Long-term Care
    Stijn Crutzen, Shiral S. Gangadin, Ken Ho Hua, Ellen Visser, Frederike Jörg, Lisette van der Meer, Gerdina H. M. Pijnenborg, Wim Veling, Stynke Castelein · 2025 · Schizophrenia Bulletin
58. Time to Rehospitalization for Different Oral Risperidone Dosing Frequencies in Patients With Schizophrenia
    Xi-Yu Wang, Hung-Yu Chan, Ching-Hua Lin · 2022 · Journal of Clinical Psychopharmacology
59. Partial agonists of dopamine receptors: theoretical principles of combining antipsychotics including partial agonists to treat schizophrenia
    John Cookson, Jonathan Pimm, Andrew S. Brentnall · 2022 · BJPsych Advances
60. Psychotic Experiences, Cognitive Decline, and Genetic Vulnerabilities in Relation to Developing Psychotic Disorders
    Ned H. Kalin · 2020 · American Journal of Psychiatry
61. Efficacy and Tolerability of Lesion Network Guided Transcranial Electrical Stimulation in Outpatients with Psychosis Spectrum Illness: A Nonrandomized Controlled Trial
    Nicolas Raymond, Robert M. G. Reinhart, Rebekah L. Trotti, David Parker, Shrey Grover, Bilge Turkozer, Dean Sabatinelli, Rachal R. Hegde, Deepthi Bannai, Swetha Gandu et al. · 2023 · medRxiv
62. Fundamental Frequency of the Voice in Schizophrenia and Its Value as a Biomarker of the Disease
    Alfonso Martínez, Roberto Fernández-Baíllo, José L. Martín‐Conty, Laura Mordillo‐Mateos, Juan José Bernal-Jiménez, Begoña Polonio López, Manuela Martínez-Lorca · 2024 · Journal of Voice
63. Association of core brain networks with antipsychotic therapeutic effects in first-episode schizophrenia
    Yuling Luo, Tianyuan Zhu, Yu Zhang, Jiamin Fan, Xiaojun Zuo, Xiaorong Feng, Jinnan Gong, Dezhong Yao, Jijun Wang, Cheng Luo · 2025 · Cerebral Cortex
64. Lurasidone for bipolar I depression with comorbid anxiety symptoms: Post-hoc-analysis of randomized, placebo-controlled studies
    Takeshi Inoue, Takahiro Masuda, Fumiya Sano, Hidenori Maruyama · 2025 · Journal of Affective Disorders
65. The Effects of Antipsychotic Dose Reduction on Movement Disorders and Cardiometabolic Indices in Patients Remitted from a First Episode of Psychosis
    Yinzhao Liu, Iris E. Sommer, Marieke Begemann, Shiral S. Gangadin, Benjamin Ian Perry, Toon Anton Willem Scheurink, Nico J.M. van Beveren, Iris E. Sommer, Lieuwe de Haan, Wim Veling et al. · 2025 · Schizophrenia Bulletin
66. Enriching Global Perspectives Through a Regional Lens: Recognition, Assessment, and Management of Tardive Dyskinesia in Southeast Asia
    Roongroj Bhidayasiri, Jin Kiat Ang, Kok Yoon Chee, Roger Ho, Ahmad Shahir Mawardi, Adhi Wibowo Nurhidayat, Pongsatorn Paholpak, Pornjira Pariwatcharakul, Thitima Sanguanvichaikul, Eng Khean Ung et al. · 2025 · Journal of Movement Disorders
67. Brexpiprazole for agitation in alzheimer’s disease: A systematic review and meta-analysis of randomized controlled trials
    João Vítor Andrade Fernandes, João Victor de Oliveira Ramos, Laís Araújo dos Santos Vilar, Maurus Marques de Almeida Holanda · 2025 · Indian Journal of Psychiatry
68. Association between the exposome score for schizophrenia and functioning in remitted first-episode psychosis: results from the HAMLETT study
    Sterre Kamphuis, Angelo Arias-Magnasco, Shiral S. Gangadin, Marieke Begemann, Ben F. M. Wijnen, Wim Veling, Lieuwe de Haan, Iris E. Sommer, Jim van Os, Pieter Roberto Bakker et al. · 2025 · Schizophrenia Research
69. Comparative Efficacy and Tolerability of Multiple Antipsychotics Across Varying Doses for Neuropsychiatric Symptoms of Dementia Including Alzheimer's Disease: A Dose–Response Model‐Based Network Meta‐Analysis
    Itsuki Terao, Wakako Kodama · 2025 · Acta Psychiatrica Scandinavica
70. Medication and atypical brain maturation in psychosis associated with long-term cognitive decline and symptom progression
    Claudio Alemán-Morillo, Natalia García-San-Martín, Richard A. I. Bethlehem, Lena Dorfschmidt, María Alemany-Navarro, Patricia Segura, Alessia Pasquini, Manuel Muñoz‐Caracuel, Manuel Canal‐Rivero, Jakob Seidlitz et al. · 2025 · The British Journal of Psychiatry
71. Negative association between cognitive functioning and antipsychotic D 2 receptor occupancy, affinity, and dose after first episode psychosis
    Priscilla P. Oomen, Shiral S. Gangadin, Lieuwe de Haan, Franciska de Beer, Oda E. Beune, Doris A.D. Oostendorp, Marieke Begemann, Nynke Boonstra, Martijn Kikkert, Sanne Koops et al. · 2026 · Psychological Medicine
72. Formal thought disorder and familial risk in first-episode psychosis: A study of cortical thickness and neuroimaging-transcriptomic association analysis
    Tuğçe Çabuk, Yuanchao Zhang, Lena K. Palaniyappan, Didenur Şahin-Çevik, Hanife Avcı, Işık Batuhan Çakmak, Helin Yılmaz Kafalı, Bedirhan Şenol, Kader Karlı Oğuz, Timothea Toulopoulou · 2026 · Psychiatry Research Neuroimaging
73. Antipsychotic plasma concentration as predictor of movement disorders and cardiometabolic side-effects: A comparison with prescription dose
    Yinzhao Liu, Iris E. Sommer, Georgios Schoretsanitis, Iris M. H. Hamers, Toon Anton Willem Scheurink, Marieke Begemann, Shiral S. Gangadin, Nico J.M. van Beveren, Iris E. Sommer, Lieuwe de Haan et al. · 2026 · European Neuropsychopharmacology
74. Low incidence of extrapyramidal symptoms following treatment with a muscarinic agonist medication for schizophrenia
    Steven D. Targum, Carolyn B. Watson, Amy Claxton, Pierre Nicolas, Keisha D. Novak, Inder Kaul, Stephen R. Marder, Wei-Chih Lin, William P. Horan, Ronald N. Marcus et al. · 2026 · Schizophrenia Research
75. Early Clinical Symptom Patterns Predict the Subsequent Treatment Response of Patients with Acute Schizophrenia
    Zhaofan Liu, Wenjin Chen, X. Q. Wang, Junchao Huang, Mengzhuang Gou, Han Han, J P Wang, Da-Hui Wang, Song Chen, Ting Xie et al. · 2026 · Schizophrenia Bulletin
76. Cortical morphometry might predict currently prescribed vs. discontinued medications in bipolar disorder, even after controlling for the cumulative dose effects: An ENIGMA mega-analysis
    Lydia Fortea, Miguel Ángel Rivas‐Fernández, Aleix Solanes, Sinéad King, Leila Nabulsi, Martin Alda, Nina Alexander, Jochen Bauer, Francesco Benedetti, Tiana Borgers et al. · 2026 · Molecular Psychiatry
77. Psychopharmakotherapie bei schizophrenen Patient:innen im Maßregelvollzug – evidenzbasierte Psychopharmakotherapie zwischen Leitlinien, klinischer Realität und forensischen Spezifika
    Julia Krebs · 2026 · Forensische Psychiatrie Psychologie Kriminologie
78. Long-acting drug delivery systems for schizophrenia treatment
    V. Sreeraj, Venkataram Shivakumar, Na-Ren P. Rao, G. Venkatasubramanian · 2022 · Long-Acting Drug Delivery Systems
79. Limitations in Research on Maintenance Treatment for Individuals With Schizophrenia—Reply
    Stefan Leucht, Spyridon Siafis, John M. Davis · 2021 · JAMA Psychiatry
80. Clinical Phenotype of Tardive Dyskinesia in Bipolar Disorder
    Manuel Gardea‐Resendez, Monica J. Taylor-Desir, Francisco Romo‐Nava, David J. Bond, Eric J. Vallender, Alfredo B. Cuellar-Barboza, Miguel L. Prieto, Nicolas Nunez, Marin Veldic, Ayşegül Özerdem et al. · 2022 · Journal of Clinical Psychopharmacology
81. Elevated triglycerides and low triiodothyronine: Key risk factors for coronary artery calcification in patients with schizophrenia
    Tan-yu Huang, Li-chang Chen, Xiaoping Li, Wu-hao Li, Shu‐xian Xu, Corina Nagy, Pascal Ibrahim, Zhaowen Nie, Nai-yan Yang, Lun Zeng et al. · 2023 · Schizophrenia Research
82. Long-Acting Injectable Second-Generation Antipsychotics in Seriously Ill Patients with Schizophrenia: Doses, Plasma Levels, and Treatment Outcomes
    Juan José Fernández Miranda, Silvia Díaz-Fernández, F.J. Cepeda Piorno, Francisco Javier Lopez-Munoz · 2024 · Biomedicines
83. Schizophrenia and Psychosis: Treatment and Follow-Up
    Elizabeth C. Thompson, Nicholas Meinhardt, Jon McClellan · 2024 · Issues in clinical child psychology
84. Antipsychotic Prescribing Practices for In-patients with Schizophrenia
    Aleksandr G. Sofronov, A. E. Dobrovolskaya, A. N. Gvozdetckii, I. S. Kushnerev · 2024 · Psikhiatriya
85. Antipsychotic Discontinuation and Re-initiation in Pregnant Women With Schizophrenia: A Retrospective Cohort Study From South Korea
    Jiyeon Kim, Julia Kaminska, Ye-Jee Kim, Sung Woo Joo, Bo Ram Yang · 2025 · Schizophrenia Bulletin
86. Safety and efficacy of different initial doses of lurasidone in the schizophrenia treatment: A multi-center, randomized, open-label study
    Qi Liu, Mincai Qian, Zhifen Liu, Fang Dong, Dengtang Liu, Mingli Li, Yu-Ping Ning, Xiaoping Wang, Tiebang Liu, Qi Wu et al. · 2025 · World Journal of Psychiatry
87. Aripiprazole – from research results to clinical practice
    Oddział Chorób Afektywnych, Instytut Psychiatrii i Neurologii, Warszawa, Polska, Anna Antosik-Wójcińska · 2020 · Psychiatria i Psychologia Kliniczna
88. Bell-shaped dose-response curve of antipsychotic drugs and dopaminergic auto-receptors: a hypothesis
    Kentaro Kohno, Takeshi Terao, Hirofumi Hirakawa, Nobuyoshi Ishii · 2020 · Clinical Neuropsychopharmacology and Therapeutics
89. Monitoring of the Antipsychotic Therapy Effectiveness
    И. И. Мирошниченко · 2023 · Psikhiatriya
90. Optimal dose for the efficacy of asenapine in patients with schizophrenia: Real‐world data
    Yoshiteru Takekita, Shuichi Hiraoka, Yasuhiro Iwama, Daisuke Matsui, Nobuatsu Aoki, Haruhiko Ogata, Toshiya Funatsuki, Toshiyuki Shimizu, Yuji Murase, Yosuke Koshikawa et al. · 2023 · Neuropsychopharmacology Reports
91. Choosing an Optimal Antipsychotic Dose for Relapse Prevention
    John M. Davis, Hua Jin · 2022 · Schizophrenia Bulletin
92. Comment on “An Integrated Pharmacokinetic–Pharmacodynamic–Pharmacoeconomic Modeling Method to Evaluate Treatments for Adults with Schizophrenia”
    Bhaskar Rege, James A McGrory, Sabina Gasper, David McDonnell · 2022 · PharmacoEconomics
93. Plasmatic Levels and Response to Variable Doses of Monthly Aripiprazole and Three-Month Paliperidone in Patients with Severe Schizophrenia. Treatment Adherence, Effectiveness, Tolerability, and Safety
    Juan José Fernández Miranda, Silvia Díaz-Fernández · 2023 · Neuropsychiatric Disease and Treatment
94. “Adequate dose” in the drug treatment of mental disorders
    В. Л. Козловский, N. V. Kozlovskaya, Dmitry N. Kosterin, Лепик Ольга Витальевна, Mikhail Yu. Popov · 2024 · V M BEKHTEREV REVIEW OF PSYCHIATRY AND MEDICAL PSYCHOLOGY
95. Modeling Decision-Making in Schizophrenia: Associations Between Computationally Derived Risk Propensity and Self-Reported Risk Perception
    Emma N. Herms, Joshua W. Brown, Krista Wisner, William P. Hetrick, David Harold Zald, John R Purcell · 2024 · Schizophrenia Bulletin
96. Semantic Processing Deficits and Their Use as Early Biomarkers in Schizophrenia
    Alfonso Martínez, Begoña Polonio López, Juan José Bernal-Jiménez, José L. Martín‐Conty, Laura Mordillo‐Mateos, Manuela Martínez-Lorca · 2025 · Healthcare
97. Targeting neurochemical and immune dysregulation in schizophrenia: From molecular mechanisms to emerging therapeutic strategies
    Aastha Datta, Himani Rana, Shareen Singh, Thakur Gurjeet Singh · 2025 · Progress in Neuro-Psychopharmacology and Biological Psychiatry
98. Psychological side effects of antipsychotic medication after remission from first-episode psychosis: a HAMLETT ecological momentary assessment study
    Matej Djordjevic, Shiral S. Gangadin, Lieuwe de Haan, Hannah E. Jongsma, Priscilla P. Oomen, Claudia J.P. Simons, Machteld C. Marcelis, Mark Nijland, Marieke Begemann, Iris E. Sommer et al. · 2025 · Psychological Medicine
99. Altered neural processing in middle frontal gyrus and cerebellum during temporal recalibration of action-outcome predictions in schizophrenia spectrum disorders
    Christina Victoria Schmitter, Benjamin Straube · 2026 · Schizophrenia
100. Antipsychotic prescribing patterns in a state psychiatric hospital with predominantly forensic admissions
     Nina Vadiei · 2026 · Frontiers in Psychiatry